Article| December 2022 Supply Chain Concerns and the Effect on Health Care Systems: Essential Considerations for Anesthesia Providers George Tewfik, MD, MBA, FASA; George Tewfik, MD, MBA, FASA Search for other works by this author on: This Site PubMed Google Scholar Samuel Mark Paschall Samuel Mark Paschall Search for other works by this author on: This Site PubMed Google Scholar ASA Monitor December 2022, Vol. 86, 1–8. https://doi.org/10.1097/01.ASM.0000904200.47110.56 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Search Site Citation George Tewfik, Samuel Mark Paschall; Supply Chain Concerns and the Effect on Health Care Systems: Essential Considerations for Anesthesia Providers. ASA Monitor 2022; 86:1–8 doi: https://doi.org/10.1097/01.ASM.0000904200.47110.56 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsASA Monitor Search Advanced Search Topics: health care systems Health care workers, and anesthesia providers specifically, had likely never given much thought to supply chains until the start of the COVID-19 pandemic. As the world shut down, and we shifted our practices to emergency procedures, careful intubations, and ventilator management, our televisions were inundated with images of bare shelves in the supermarkets, with shoppers suddenly hoarding home essentials such as toilet paper and disinfectant wipes. Since that time, disruptions in the supply chain have affected consumer goods such as semiconductors, computer chips, and infant formula. Medical devices and medications have experienced supply chain issues that existed before the tumult of the last several years. A national shortage of propofol occurred in 2010 that caused anesthesia providers to quickly shift to alternate induction agents. This shortage was attributed to two major problems. The first was manufacturer hesitancy to make drugs with high liability risk, following a court ruling that held... You do not currently have access to this content.